Demographics for patients with and without investigator-reported tMDS/tAML
Demographic characteristic . | Investigator-reported tMDS/tAML . | No investigator-reported tMDS/tAML . |
|---|---|---|
| No. patients | 35 | 960 |
| Sex | ||
| Male, no. (%) | 21 (60) | 565 (59) |
| Female, no. (%) | 14 (40) | 395 (41) |
| Median age, y (range) | 59 (41-81) | 58 (21-88) |
| Median time from diagnosis to protocol entry, mo (range) | 43 (8-214) | 45 (2-334) |
| Grade at protocol entry, no. (%) | ||
| Low grade | 26 (74) | 740 (77) |
| Transformed low grade | 8 (23) | 210 (22) |
| Intermediate/high grade | 1 (3) | 10 (1) |
| Ann Arbor stage III/IV at enrollment, no. (%) | 31 (89) | 852 (89) |
| Bone marrow involvement, no. (%) | 15/34 (44) | 399/956 (42) |
| Elevated LDH, no. (%) | 4/20 (20) | 86/204 (42) |
| Decreased platelets,* no. (%) | 17 (49) | 228 (24) |
| Decreased ANC,† no. (%) | 16 (46) | 285 (30) |
| Median number of prior therapies (range) | 3 (1-13) | 3 (1-13) |
| Patients with 4 or more prior therapies, no. (%) | 16 (46) | 335 (35) |
| Previously received rituximab, no. (%) | 10 (29) | 460 (48) |
| Previously received fludarabine, no. (%) | 13/20 (65) | 90/210 (43) |
| Previously received anthracycline or anthracenedione, no. (%) | 18/20 (90) | 167/210 (80) |
| Previously received alkylator, no. (%) | 19/20 (95) | 208/210 (99) |
| Previously received radiotherapy, no. (%) | 11 (31) | 233 (24) |
Demographic characteristic . | Investigator-reported tMDS/tAML . | No investigator-reported tMDS/tAML . |
|---|---|---|
| No. patients | 35 | 960 |
| Sex | ||
| Male, no. (%) | 21 (60) | 565 (59) |
| Female, no. (%) | 14 (40) | 395 (41) |
| Median age, y (range) | 59 (41-81) | 58 (21-88) |
| Median time from diagnosis to protocol entry, mo (range) | 43 (8-214) | 45 (2-334) |
| Grade at protocol entry, no. (%) | ||
| Low grade | 26 (74) | 740 (77) |
| Transformed low grade | 8 (23) | 210 (22) |
| Intermediate/high grade | 1 (3) | 10 (1) |
| Ann Arbor stage III/IV at enrollment, no. (%) | 31 (89) | 852 (89) |
| Bone marrow involvement, no. (%) | 15/34 (44) | 399/956 (42) |
| Elevated LDH, no. (%) | 4/20 (20) | 86/204 (42) |
| Decreased platelets,* no. (%) | 17 (49) | 228 (24) |
| Decreased ANC,† no. (%) | 16 (46) | 285 (30) |
| Median number of prior therapies (range) | 3 (1-13) | 3 (1-13) |
| Patients with 4 or more prior therapies, no. (%) | 16 (46) | 335 (35) |
| Previously received rituximab, no. (%) | 10 (29) | 460 (48) |
| Previously received fludarabine, no. (%) | 13/20 (65) | 90/210 (43) |
| Previously received anthracycline or anthracenedione, no. (%) | 18/20 (90) | 167/210 (80) |
| Previously received alkylator, no. (%) | 19/20 (95) | 208/210 (99) |
| Previously received radiotherapy, no. (%) | 11 (31) | 233 (24) |